

# Cecile Le Pechoux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8586589/publications.pdf>

Version: 2024-02-01

51  
papers

1,306  
citations

516710

16  
h-index

434195

31  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1565  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy + brachytherapy association. <i>Oral Oncology</i> , 2022, 125, 105715.	1.5	1
2	Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 556-566.	1.6	17
3	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 104-114.	10.7	123
4	Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 170, 95-101.	0.6	2
5	Treatment related factors associated with the risk of breast radio-induced-sarcoma. <i>Radiotherapy and Oncology</i> , 2022, 171, 14-21.	0.6	6
6	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. <i>Journal of Surgical Oncology</i> , 2021, 123, 12-23.	1.7	7
7	Thoracic radiotherapy in small cell lung cancer – a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2059-2070.	2.8	14
8	Evolving target volume concepts in locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1999-2010.	2.8	8
9	Tumour motion management in lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2011-2017.	2.8	7
10	Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2021, 158, 40-47.	0.6	7
11	Surgical management of soft tissue tumors of the abdominal wall: A retrospective study in a high-volume sarcoma center. <i>Journal of Surgical Oncology</i> , 2021, 124, 679-686.	1.7	4
12	Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer. <i>Lancet Oncology</i> , The, 2021, 22, e220.	10.7	1
13	Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 79-84.	1.7	1
14	Stage III NSCLC in Low- and Middle-Income Countries: Where Are We in 2021?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1605-1606.	1.1	1
15	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. <i>Radiotherapy and Oncology</i> , 2021, 154, 125-127.	0.6	7
16	Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. <i>Radiotherapy and Oncology</i> , 2021, 164, 163-166.	0.6	0
17	Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. <i>Lung Cancer</i> , 2021, 162, 96-105.	2.0	17
18	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1147-1157.	6.4	103

#	ARTICLE	IF	CITATIONS
19	Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREO-SARC trial protocol. <i>BMJ Open</i> , 2020, 10, e038391.	1.9	12
20	Hippocampal Avoidance Whole-Brain Radiotherapy (WBRT) Versus WBRT in Patients With Brain Metastases: Were Hippocampi the Only Difference?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3453-3454.	1.6	2
21	Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases. <i>JAMA Oncology</i> , 2020, 6, 1037.	7.1	7
22	Multimodal approach: combining radiation therapy with immunotherapy in solid tumors. <i>Future Oncology</i> , 2020, 16, 1669-1671.	2.4	0
23	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 89-95.	0.6	23
24	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise. <i>Radiotherapy and Oncology</i> , 2020, 150, 26-29.	0.6	13
25	<sup>18</sup> F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [ <sup>18</sup> F]FDG PET-MRI data. <i>EJNMMI Research</i> , 2020, 10, 88.	2.5	7
26	Check the Reports and Check the Brain. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 711-712.	0.8	0
27	Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988553.	2.6	32
28	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. <i>Lung Cancer</i> , 2019, 136, 145-147.	2.0	17
29	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1230-1239.	2.0	2
30	Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 294-297.	1.1	17
31	Is dose de-escalation possible in sarcoma patients treated with enlarged limb sparing resection?. <i>Radiotherapy and Oncology</i> , 2018, 126, 493-498.	0.6	7
32	Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2018, 8, 336.	2.8	26
33	Prophylactic Cranial Irradiation or No Prophylactic Cranial Irradiation after Adjuvant Chemotherapy in Resected Small Cell Lung Cancer?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 173-175.	1.1	7
34	The Current Role of Whole Brain Radiation Therapy in Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1467-1477.	1.1	18
35	Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1715-1722.	1.1	25
36	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 1-10.	0.6	177

#	ARTICLE	IF	CITATIONS
37	Primary Extremity Soft Tissue Sarcomas: Does Local Control Impact Survival?. <i>Annals of Surgical Oncology</i> , 2017, 24, 194-201.	1.5	64
38	Stereotactic ablative body radiation therapy or surgery for operable early non-small cell lung cancer patients: bound hand and foot to evidence. <i>Journal of Thoracic Disease</i> , 2017, 9, 482-484.	1.4	2
39	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 15924-15933.	1.8	16
40	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 25189-25199.	1.8	12
41	Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. <i>Radiotherapy and Oncology</i> , 2016, 120, 156-162.	0.6	8
42	Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1940-1953.	1.1	23
43	Postoperative radiotherapy for non-small cell lung cancer. , 2016, 9, CD002142.		25
44	Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1538-1549.	1.1	22
45	Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse. <i>Cancer Treatment Reviews</i> , 2016, 50, 240-246.	7.7	38
46	In Regard to Koshy et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 945-946.	0.8	5
47	High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2014, 15, e620-e624.	10.7	76
48	Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?. <i>Translational Lung Cancer Research</i> , 2014, 3, 195-204.	2.8	4
49	Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer. <i>European Journal of Cancer</i> , Supplement, 2013, 11, 123-130.	2.2	15
50	Need for a New Trial to Evaluate Adjuvant Postoperative Radiotherapy in Non-“Small-Cell Lung Cancer Patients With N2 Mediastinal Involvement. <i>Journal of Clinical Oncology</i> , 2007, 25, e10-e11.	1.6	55
51	A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. , 1999, 86, 265-273.		223